In GCPMs:
• YAP1 inhibition → ↑ TAZ activation
• TAZ forms complexes with TEAD4 and AP-1 (c-JUN/FOSB)
• Drives transcription of oncogenic targets (e.g., SOX9, BIRC5, CTGF, CYR61)
➡️ A key mechanism of therapy resistance via transcriptional plasticity
#TumorPlasticity #TherapyResistance

SMLR1 engages TAM markers MRC1 (CD206) & SIGLEC1 (CD169), linking metastatic CRC cells to immunosuppressive macrophages in the liver niche.
A potential immune-evasion mechanism in CRLM.

CHP 2024;1(1):0003
#TumorPlasticity #ImmuneEvasion

📘 CHP Archive Spotlight #01
Inaugural Editorial (2024)

EIC Dean Tang outlines CHP’s mission: dissecting how cancer heterogeneity, plasticity & tumor microenvironment interactions drive therapy resistance, metastasis & recurrence.

📖 CHP 2024;1(1):0001
🔗 doi.org/10.47248/chp...
#TumorPlasticity

Keynote by Dana Pe'er on tumor plasticity at #EACR2025 this was truly mind-blowing! Incredible integration of cutting-edge mouse models and bioinformatics tools. Thank you for sharing such visionary work! #CancerResearch #TumorPlasticity #SingleCell